<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34588483</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1<sup>G93A</sup> mice with a C57BL/6 background.</ArticleTitle><Pagination><StartPage>19392</StartPage><MedlinePgn>19392</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">19392</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-98317-w</ELocationID><Abstract><AbstractText>The synthetic copper-containing compound, CuATSM, has emerged as one of the most promising drug candidates developed for the treatment of amyotrophic lateral sclerosis (ALS). Multiple studies have reported CuATSM treatment provides therapeutic efficacy in various mouse models of ALS without any observable adverse effects. Moreover, recent results from an open label clinical study suggested that daily oral dosing with CuATSM slows disease progression in patients with both sporadic and familial ALS, providing encouraging support for CuATSM in the treatment of ALS. Here, we assessed CuATSM in high copy SOD1<sup>G93A</sup> mice on the congenic C57BL/6 background, treating at 100&#xa0;mg/kg/day by gavage, starting at 70&#xa0;days of age. This dose in this specific model has not been assessed previously. Unexpectedly, we report a subset of mice initially administered CuATSM exhibited signs of clinical toxicity, that necessitated euthanasia in extremis after 3-51&#xa0;days of treatment. Following a 1-week washout period, the remaining mice resumed treatment at the reduced dose of 60&#xa0;mg/kg/day. At this revised dose, treatment with CuATSM slowed disease progression and increased survival relative to vehicle-treated littermates. This work provides the first evidence that CuATSM produces positive disease-modifying outcomes in high copy SOD1<sup>G93A</sup> mice on a congenic C57BL/6 background. Furthermore, results from the 100&#xa0;mg/kg/day phase of the study support dose escalation determination of tolerability as a prudent step when assessing treatments in previously unassessed models or genetic backgrounds.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lum</LastName><ForeName>Jeremy S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Mikayla L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrawell</LastName><ForeName>Natalie E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAlary</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ly</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chisholm</LastName><ForeName>Christen G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snow</LastName><ForeName>Josh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vine</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karl</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreilaus</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInnes</LastName><ForeName>Lachlan E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikseresht</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crouch</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, VIC, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerbury</LastName><ForeName>Justin J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia. jyerbury@uow.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia. jyerbury@uow.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000720849">CuATSM</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091343">Organocopper Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091343" MajorTopicYN="Y">Organocopper Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Collaborative Medicinal Development LLC has licensed intellectual property related to this subject from the University of Melbourne where the inventors include PSD. PJC is an unpaid consultant for Collaborative Medicinal Development LLC. JSL, MLB, NEF, LM, DL, CGC, JS, KLV, TK, FK, LEM, SN, JJY declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34588483</ArticleId><ArticleId IdType="pmc">PMC8481268</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-98317-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-98317-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Appel SH. Introduction to supplement: The current status of treatment for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:1&#x2013;4. doi: 10.1080/21678421.2017.1361447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361447</ArticleId><ArticleId IdType="pubmed">28872909</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. July 2017 ENCALS statement on edaravone. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:471&#x2013;474. doi: 10.1080/21678421.2017.1369125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, et al. Development of a smartphone app for a genetics website: The Amyotrophic Lateral Sclerosis Online Genetics Database (ALSoD) JMIR mHealth uHealth. 2013;1:e18. doi: 10.2196/mhealth.2706.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/mhealth.2706</ArticleId><ArticleId IdType="pmc">PMC4114449</ArticleId><ArticleId IdType="pubmed">25098641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat J-M, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. U.S.A. 1994;91:8292&#x2013;8296. doi: 10.1073/pnas.91.17.8292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.17.8292</ArticleId><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996;13:43&#x2013;47. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS) Brain Res. 1995;676:25&#x2013;40. doi: 10.1016/0006-8993(95)00063-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(95)00063-V</ArticleId><ArticleId IdType="pubmed">7796176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D, et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 2000;7:623&#x2013;643. doi: 10.1006/nbdi.2000.0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0299</ArticleId><ArticleId IdType="pubmed">11114261</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 2008;85:94&#x2013;134. doi: 10.1016/j.pneurobio.2008.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2008.01.001</ArticleId><ArticleId IdType="pubmed">18282652</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L, Yerbury JJ. Strategies to promote the maturation of ALS-associated SOD1 mutants: Small molecules return to the fold. Neural Regen. Res. 2019;14:1511&#x2013;1512. doi: 10.4103/1673-5374.255962.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.255962</ArticleId><ArticleId IdType="pmc">PMC6557088</ArticleId><ArticleId IdType="pubmed">31089043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei G, et al. Denaturation of human copper-zinc superoxide dismutase by guanidine hydrochloride: A dynamic fluorescence study. Biochemistry. 1992;31:7224&#x2013;7230. doi: 10.1021/bi00147a003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00147a003</ArticleId><ArticleId IdType="pubmed">1510915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JA, et al. Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J. Biol. Chem. 2002;277:15932&#x2013;15937. doi: 10.1074/jbc.M112088200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112088200</ArticleId><ArticleId IdType="pubmed">11854285</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2014;34:8021&#x2013;8031. doi: 10.1523/JNEUROSCI.4196-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4196-13.2014</ArticleId><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JR, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol. Dis. 2016;89:1&#x2013;9. doi: 10.1016/j.nbd.2016.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.01.020</ArticleId><ArticleId IdType="pmc">PMC4785045</ArticleId><ArticleId IdType="pubmed">26826269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton JB, White AR, Crouch PJ. Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS. Metallomics. 2016;8:1002&#x2013;1011. doi: 10.1039/C6MT00099A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6MT00099A</ArticleId><ArticleId IdType="pubmed">27357743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton JB, et al. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. 2017;7:42292. doi: 10.1038/srep42292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42292</ArticleId><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan JY, et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: Correlating 7 Tesla MRI and pathology. PLoS&#xa0;One. 2012;7:e35241. doi: 10.1371/journal.pone.0035241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035241</ArticleId><ArticleId IdType="pmc">PMC3328441</ArticleId><ArticleId IdType="pubmed">22529995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton, J. B. Disrupted copper availability in sporadic ALS: Implications for CuII (atsm) as a treatment option. Preprint at https://www.biorxiv.org/content/10.1101/2020.04.17.047704v1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.17.047704v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Soon CPW, et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 2011;286:44035&#x2013;44044. doi: 10.1074/jbc.M111.274407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.274407</ArticleId><ArticleId IdType="pmc">PMC3243559</ArticleId><ArticleId IdType="pubmed">22033929</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllum EJ, et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013;14:586&#x2013;590. doi: 10.3109/21678421.2013.824000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.824000</ArticleId><ArticleId IdType="pubmed">23952668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung LW, et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson&#x2019;s disease. J. Exp. Med. 2012;209:837&#x2013;854. doi: 10.1084/jem.20112285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112285</ArticleId><ArticleId IdType="pmc">PMC3328361</ArticleId><ArticleId IdType="pubmed">22473957</ArticleId></ArticleIdList></Reference><Reference><Citation>Huuskonen MT, et al. The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu. Neurotherapeutics. 2017;14:519&#x2013;532. doi: 10.1007/s13311-016-0504-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0504-9</ArticleId><ArticleId IdType="pmc">PMC5398983</ArticleId><ArticleId IdType="pubmed">28050710</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo XY, et al. CuII(atsm) Attenuates Neuroinflammation. Front. Neurosci. 2018;12:668. doi: 10.3389/fnins.2018.00668.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00668</ArticleId><ArticleId IdType="pmc">PMC6165894</ArticleId><ArticleId IdType="pubmed">30319344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly D, et al. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice. Purinergic Signal. 2020;16:109&#x2013;122. doi: 10.1007/s11302-020-09692-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-020-09692-4</ArticleId><ArticleId IdType="pmc">PMC7166237</ArticleId><ArticleId IdType="pubmed">32170537</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira FG, et al. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep. 2017;2:47&#x2013;53. doi: 10.1016/j.ibror.2017.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibror.2017.03.001</ArticleId><ArticleId IdType="pmc">PMC6084867</ArticleId><ArticleId IdType="pubmed">30135932</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe, D., Mathers, S. &amp; Smith, G. Modification of ALS disease progression in a phase 1 trial of CuATSM. 29th International Symposium on ALS/MND Glasgow (2018).</Citation></Reference><Reference><Citation>Hebert, C. NTP technical report on the toxicity studies of cupric sulfate (CAS No. 7758-99-8) administered in drinking water and feed to F344/N rats and B6C3F1 mice. Toxicity Report Series29, 1-D3 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">12209195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Kalita J, Misra UK, Bora HK. A study of dose response and organ susceptibility of copper toxicity in a rat model. J. Trace Elem. Med. Biol. 2015;29:269&#x2013;274. doi: 10.1016/j.jtemb.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtemb.2014.06.004</ArticleId><ArticleId IdType="pubmed">25022334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A, et al. Biochemical, histological, and memory impairment effects of chronic copper toxicity: A model for non-Wilsonian brain copper toxicosis in Wistar rat. Biol. Trace Elem. Res. 2013;153:257&#x2013;268. doi: 10.1007/s12011-013-9665-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-013-9665-0</ArticleId><ArticleId IdType="pubmed">23613148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujibayashi Y, et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 1997;38:1155&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225812</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearling J, Packard A. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl. Med. Biol. 2010 doi: 10.1016/j.nucmedbio.2009.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nucmedbio.2009.11.004</ArticleId><ArticleId IdType="pubmed">20346863</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly PS, et al. An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copperII. Proc. Natl. Acad. Sci. U.S.A. 2012;109:47&#x2013;52. doi: 10.1073/pnas.1116227108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1116227108</ArticleId><ArticleId IdType="pmc">PMC3252939</ArticleId><ArticleId IdType="pubmed">22173633</ArticleId></ArticleIdList></Reference><Reference><Citation>Padgitt-Cobb L. 234-Investigation into the oxidation of CuATSM as a mechanism for copper release. Free Radic. Biol. Med. 2016;100:S107. doi: 10.1016/j.freeradbiomed.2016.10.275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2016.10.275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirois JJ, et al. Oxidative release of copper from pharmacologic copper bis(thiosemicarbazonato) compounds. Inorg. Chem. 2018;57:8923&#x2013;8932. doi: 10.1021/acs.inorgchem.8b00853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.inorgchem.8b00853</ArticleId><ArticleId IdType="pubmed">29979041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa T, et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 2008;363:1&#x2013;25. doi: 10.1016/j.ijpharm.2008.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2008.07.009</ArticleId><ArticleId IdType="pubmed">18682282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570:462&#x2013;467. doi: 10.1038/s41586-019-1291-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1291-3</ArticleId><ArticleId IdType="pmc">PMC6597290</ArticleId><ArticleId IdType="pubmed">31158845</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr C, Hunt DM. Genetic differences in zinc and copper induction of liver metallothionein in inbred strains of the mouse. Biochem. Genet. 1989;27:199&#x2013;217. doi: 10.1007/BF02401801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02401801</ArticleId><ArticleId IdType="pubmed">2775170</ArticleId></ArticleIdList></Reference><Reference><Citation>Huster D, et al. Consequences of copper accumulation in the livers of the Atp7b&#x2212;/&#x2212; (Wilson disease gene) knockout mice. Am. J. Pathol. 2006;168:423&#x2013;434. doi: 10.2353/ajpath.2006.050312.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.050312</ArticleId><ArticleId IdType="pmc">PMC1606493</ArticleId><ArticleId IdType="pubmed">16436657</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005;236:1&#x2013;7. doi: 10.1016/j.jns.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers. Amyotroph. Lateral Scler. 2011;12:79&#x2013;86. doi: 10.3109/17482968.2010.550626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.550626</ArticleId><ArticleId IdType="pubmed">21241159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012;13:302&#x2013;310. doi: 10.3109/17482968.2012.662688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.662688</ArticleId><ArticleId IdType="pubmed">22424126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl SR, Halicek MT, Mitchell CS. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: A meta-analysis. J. Neuromusc. Dis. 2015;2:137&#x2013;150. doi: 10.3233/JND-140068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-140068</ArticleId><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp PS, Dick JRT, Greensmith L. The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neuroscience. 2005;130:897&#x2013;910. doi: 10.1016/j.neuroscience.2004.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2004.09.069</ArticleId><ArticleId IdType="pubmed">15652988</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, Gonzalez de Aguilar J-L, Loeffler J-P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. U.S.A. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell NE, Yerbury MR, Plotkin SS, McAlary L, Yerbury JJ. CuATSM protects against the in vitro cytotoxicity of wild-type-like copper-zinc superoxide dismutase mutants but not mutants that disrupt metal binding. ACS Chem. Neurosci. 2019;10:1555&#x2013;1564. doi: 10.1021/acschemneuro.8b00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00527</ArticleId><ArticleId IdType="pubmed">30462490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo MTH, Beckman JS, Shaw CA. Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model. Neurobiol. Dis. 2019;130:104495. doi: 10.1016/j.nbd.2019.104495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104495</ArticleId><ArticleId IdType="pubmed">31181282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikseresht S, Hilton JBW, Kysenius K, Liddell JR, Crouch PJ. Copper-ATSM as a treatment for ALS: Support from mutant SOD1 models and beyond. Life. 2020;10:271. doi: 10.3390/life10110271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life10110271</ArticleId><ArticleId IdType="pmc">PMC7694234</ArticleId><ArticleId IdType="pubmed">33158182</ArticleId></ArticleIdList></Reference><Reference><Citation>Southon A, et al. CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br. J. Pharmacol. 2020;177:656&#x2013;667. doi: 10.1111/bph.14881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14881</ArticleId><ArticleId IdType="pmc">PMC7012947</ArticleId><ArticleId IdType="pubmed">31655003</ArticleId></ArticleIdList></Reference><Reference><Citation>Blower, P. J. et al. Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans. 4416&#x2013;4425 (2003). 10.1039/B307499D.</Citation></Reference><Reference><Citation>Hatzipetros T, et al. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. J. Vis. Exp. 2015 doi: 10.3791/53257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/53257</ArticleId><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Karl T, Pabst R, von H&#xf6;rsten S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp. Toxicol. Pathol. 2003;55:69&#x2013;83. doi: 10.1078/0940-2993-00301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1078/0940-2993-00301</ArticleId><ArticleId IdType="pubmed">12940631</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671&#x2013;675. doi: 10.1038/nmeth.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp C, Fridovich I. Superoxide dismutase: Improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 1971;44:276&#x2013;287. doi: 10.1016/0003-2697(71)90370-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(71)90370-8</ArticleId><ArticleId IdType="pubmed">4943714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>